

## **ANTI-TUMOR EFFECTS THAT GA-40 REALIZES IN PATIENTS WITH MELANOMA**

Skin melanoma is a malignant tumor, which, due to its aggressive biological properties, surpasses most types of cancer in terms of tumor progression, frequency of recurrence and metastasis, and demonstrates low survival rates. The preparation GA-40 proved its efficiency in treating this skin melanoma, which was also confirmed at the cellular level.

The immunotropic preparation GA-40 was approved by order of the Ministry of Health of Ukraine No. 263 dated 05.25.07 (No. reg. Certificate. IA / 6435/01/01 /) for medical use as an immunocorrector in the complex treatment of carcinoma patients, patients with hematological profile, as well as benign neoplasms - mastopathy, uterine fibroids, prostate adenoma.

In patients with skin melanoma, the preparation was used as a subcutaneous or intramuscular injection with a solution of 5 ml of water for injection of lyophilized powder of plant polypeptides (1000 µg) in a bottle. A single dose is 2 mcg / kg body weight. The course of treatment is 21 injections according to the scheme: two injections per week (4-5 weeks), the following weeks - 1 injection per week.

GA-40 preparation used in patients with skin melanoma confirmed high antitumor activity: multifocal necrosis of the neoplastic parenchyma and irreversible changes in the nuclear apparatus of tumor cells with increased yield of apoptosis were observed in the tumor tissue (Fig. 1).




Fig.1. Tumor cell karyolysis (A), apoptosis (B) and surrounding tumor tissue with a connective tissue barrier (C).

*Abstracts from the original publication:*

K.A. Galakhin, V.F. Konovalenko, T.V. Gordienko. New neoadjuvant (GA-40) in complex treatment of skin melanoma patient. Pathologia. 2008;5(1):28-33.